Market Cap: $2.11B
ZI
Zymeworks Inc.
ZYME
NASDAQ (NASDAQ Global Select)USD
Market Cap: $2.11B
Zymeworks BC (Ticker: ZYME) engages in a strategic acquisition as part of its growth strategy in the competitive biotech sector, announcing an agreement to purchase shares from Theravance Biopharma. T…
Zymeworks BC (Ticker: ZYME) has announced a groundbreaking collaboration with Gandeeva Therapeutics, focusing on high-resolution cryo electron microscopy (EM) to explore the structural intricacies of…
Zymeworks BC (Ticker: ZYME) collaborates with Gandeeva Therapeutics to advance antibody drug discovery through cutting-edge cryo-electron microscopy techniques. This partnership focuses on creating hi…
Zymeworks BC (Ticker: ZYME) is advancing its oncology portfolio with significant clinical and regulatory updates, particularly in the realm of antibody-drug conjugates (ADCs). The company recently rep…
Zymeworks Inc. strengthens its executive team with strategic appointments aimed at enhancing its capabilities in the competitive biotechnology landscape. Kristin Stafford is appointed as Chief Financi…
Zymeworks BC: Advancing Biotherapeutics Amid Economic Uncertainty Zymeworks BC, a prominent player in the biopharmaceutical industry, continues to innovate and advance its biotherapeutic solutions, fo…
Zymeworks BC: Navigating Innovations in Biopharmaceuticals Amid Market Uncertainties Zymeworks BC continues to solidify its position in the biopharmaceutical industry with its cutting-edge therapeutic…
Zymeworks Charts Course for Future Growth with Promising Financial Indicators Zymeworks, a clinical-stage biopharmaceutical company, announces strong Q4 results, reflecting its aggressive strides in a…
Zymeworks Marks Substantial Progress in Q4 Earnings Report Zymeworks, a prominent player in the biopharmaceutical sector, reveals promising developments in its Q4 earnings report released on March 2,…
Zymeworks: Increased Investor Interest Signals Potential Growth Zymeworks Inc. demonstrates a notable rise in investor interest as its stock experiences a significant surge in trading volume. On Monda…
Zymeworks BC Gains Momentum Amid Rising Investor Interest Zymeworks Inc. is currently experiencing a surge in interest from investors, as evidenced by a dramatic increase in its trading volume. On Mon…
Zymeworks' Focus on Innovative Therapeutics in Biopharmaceuticals Zymeworks BC, a biopharmaceutical company specializing in the development of innovative therapeutic solutions, is making strides in tr…
Zymeworks: Navigating Diverse Analyst Opinions Amidst Market Challenges Zymeworks BC is currently at a pivotal point in its growth trajectory within the biopharmaceutical sector, as reflected by the r…
Zymeworks BC: Navigating Diverse Analyst Ratings Amidst Market Complexity Zymeworks BC, a prominent player in the biopharmaceutical sector, finds itself at a pivotal point as it navigates a landscape…
### Advancements in Immunotherapy: GT Biopharma's Promising Clinical Trials GT Biopharma, Inc., a clinical-stage immunotherapy company, is making significant headway in the battle against difficult-to…
Zymeworks Reassesses Development Strategy with Discontinuation of ZW171 Zymeworks Inc. has announced a significant shift in its clinical development strategy with the voluntary halt of ZW171, a T-cell…